Challenges with COVID-19 Antibody Treatments for Omicron Variant

SOURCE apnews.com
Doctors are warning of a challenge as the two standard drugs used to treat early COVID-19 infections are unlikely to work against the new omicron variant. The antibody drugs from Regeneron and Eli Lilly are less potent against omicron, but a drug from GlaxoSmithKline appears to be effective. The U.S. is rationing scarce drug supplies and focusing on high-risk patients. Antiviral pills from Pfizer and Merck may soon be authorized as treatments.

Key Points

  • Antibody drugs used to treat early COVID-19 infections may be less effective against the new omicron variant
  • GlaxoSmithKline's antibody drug is positioned well to fight omicron
  • High-risk patients are being prioritized for antibody treatment
  • Antiviral pills from Pfizer and Merck could provide alternative treatments for COVID-19

Pros

  • GlaxoSmithKline's antibody drug appears to be effective against the omicron variant
  • Antiviral pills from Pfizer and Merck show potential in treating COVID-19 at home

Cons

  • The antibody drugs from Regeneron and Eli Lilly are less potent against the omicron variant